Trial Outcomes & Findings for Sleep Apnea Study in Adults Using DreamPort-Eclipse and a Traditional Nasal Mask (NCT NCT05818540)

NCT ID: NCT05818540

Last Updated: 2025-11-10

Results Overview

AHI recorded from the software built-in algorithm. The Apnea-Hypopnea Index or Apnoea-Hypopnoea Index (AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The apneas (pauses in breathing) must last for at least 10 seconds and be associated with a decrease in blood oxygenation.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

173 participants

Primary outcome timeframe

60 days

Results posted on

2025-11-10

Participant Flow

Newly diagnosed OSA patients, were recruited from SCMT centers.

Participant milestones

Participant milestones
Measure
Traditional CPAP Mask
Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night. ResMed P-10 mask: Participants will wear the mask for 6 hours a night for 60 days.
Eclipse Novel Mask
Human subjects will use the Eclipse CPAP interface for 60 days for a total of 6 hours per night. Eclipse novel CPAP mask: Participants will wear the mask for 6 hours a night for 60 days.
Overall Study
STARTED
99
74
Overall Study
COMPLETED
54
30
Overall Study
NOT COMPLETED
45
44

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Sleep Apnea Study in Adults Using DreamPort-Eclipse and a Traditional Nasal Mask

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Eclipse Novel Mask
n=30 Participants
Human subjects will use the Eclipse CPAP interface for 60 days for a total of 6 hours per night. Eclipse novel CPAP mask: Participants will wear the mask for 6 hours a night for 60 days.
Traditional CPAP Mask
n=54 Participants
Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night. ResMed P-10 mask: Participants will wear the mask for 6 hours a night for 60 days.
Total
n=84 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Age, Categorical
Between 18 and 65 years
30 Participants
n=5 Participants
53 Participants
n=20 Participants
83 Participants
n=40 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
1 Participants
n=20 Participants
1 Participants
n=40 Participants
Age, Continuous
46.4 years
STANDARD_DEVIATION 11.2 • n=5 Participants
58.5 years
STANDARD_DEVIATION 9.5 • n=20 Participants
47.8 years
STANDARD_DEVIATION 10.2 • n=40 Participants
Sex: Female, Male
Female
14 Participants
n=5 Participants
24 Participants
n=20 Participants
38 Participants
n=40 Participants
Sex: Female, Male
Male
16 Participants
n=5 Participants
30 Participants
n=20 Participants
46 Participants
n=40 Participants
Race/Ethnicity, Customized
Completed participants · White
19 Participants
n=5 Participants
43 Participants
n=20 Participants
62 Participants
n=40 Participants
Race/Ethnicity, Customized
Completed participants · Black
10 Participants
n=5 Participants
7 Participants
n=20 Participants
17 Participants
n=40 Participants
Race/Ethnicity, Customized
Completed participants · Hispanic
1 Participants
n=5 Participants
4 Participants
n=20 Participants
5 Participants
n=40 Participants
Race/Ethnicity, Customized
Completed participants · Asian
0 Participants
n=5 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants

PRIMARY outcome

Timeframe: 60 days

Population: Participants who used the Eclipse or P10 mask over a period of 60 days and completed the trial.

AHI recorded from the software built-in algorithm. The Apnea-Hypopnea Index or Apnoea-Hypopnoea Index (AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The apneas (pauses in breathing) must last for at least 10 seconds and be associated with a decrease in blood oxygenation.

Outcome measures

Outcome measures
Measure
Eclipse Novel Mask
n=30 Participants
Human subjects used the Eclipse CPAP interface for 60 days for a total of 6 hours per night.
Traditional CPAP Mask
n=54 Participants
Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.
Apnea-Hypopnea Index (AHI)
2.7 events/h
Standard Deviation 3.3
2.5 events/h
Standard Deviation 4.7

PRIMARY outcome

Timeframe: 60 days

Population: Participants who used the Eclipse or P10 mask over a period of 60 days and completed the trial.

Data were captured from the device in L/min at 60 days. Leak is how much flow in L exits the mask while the patient wears it each min. It is recorded through proprietary algorithm undisclosed to the public by the device

Outcome measures

Outcome measures
Measure
Eclipse Novel Mask
n=30 Participants
Human subjects used the Eclipse CPAP interface for 60 days for a total of 6 hours per night.
Traditional CPAP Mask
n=54 Participants
Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.
Leak
3.66 L/min
Standard Deviation 5.38
3.01 L/min
Standard Deviation 3.36

PRIMARY outcome

Timeframe: 60 days

Population: Participants who used the Eclipse or P10 mask over a period of 60 days and completed the trial.

Therapeutic positive pressure (in cmH2O) that the device administer for 95% of the night. It is recorded through proprietary algorithm undisclosed to the public by the device.

Outcome measures

Outcome measures
Measure
Eclipse Novel Mask
n=30 Participants
Human subjects used the Eclipse CPAP interface for 60 days for a total of 6 hours per night.
Traditional CPAP Mask
n=54 Participants
Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.
CPAP Device Pressure (P95)
8.93 cmH2O
Standard Deviation 1.01
8.62 cmH2O
Standard Deviation 1.46

SECONDARY outcome

Timeframe: 60 days

Population: Participants who used the Eclipse or P10 mask over a period of 60 days and completed the trial.

A 16-item patient survey was administered to the participants in each arm at the end of the study. Patients had to answer according to a Likert scale (1: worst, 5:best). This reflects the average of all the answered items. For example, question number one had an average score of 4.48 for the eclipse mask arm and 4.12 for the standard mask arm, question number 2 had an average score of 4.40 for the eclipse mask arm and 4.42 for the standard mask arm, etc. Since all questions reflect participant satisfaction, they were averaged to provide an overall score.

Outcome measures

Outcome measures
Measure
Eclipse Novel Mask
n=30 Participants
Human subjects used the Eclipse CPAP interface for 60 days for a total of 6 hours per night.
Traditional CPAP Mask
n=54 Participants
Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.
Participant Satisfaction With the Mask Choice
4.3 score
Standard Deviation 0.4
4.1 score
Standard Deviation 0.4

SECONDARY outcome

Timeframe: 60 days

Population: Participants who used the Eclipse or P10 mask over a period of 60 days and completed the trial.

We estimated the mask tolerability as follows (as a percentage): 100\*(participants who completed the trial) / \[(participants who completed the trial) + (participants who discontinued the trial due to a desire to switch masks or poor mask compliance)\].

Outcome measures

Outcome measures
Measure
Eclipse Novel Mask
n=30 Participants
Human subjects used the Eclipse CPAP interface for 60 days for a total of 6 hours per night.
Traditional CPAP Mask
n=54 Participants
Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.
Percentage of Participants Who Could Tolerate the Mask Well (Mask Tolerability)
41 % of enrolled participants
55 % of enrolled participants

Adverse Events

Eclipse Novel Mask

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Traditional CPAP Mask

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Stuart Heathington

Bleep, LLC

Phone: 919-619-7170

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place